Merck's Keytruda Could Face Direct Competition from New Chinese Drug
Chinese drug developer BeiGene (NASDAQ: BGNE) announced on Monday strong clinical results for its cancer immunotherapy, tislelizumab. A Phase 3 trial tested the drug alongside two other chemotherapy treatments in patients with non-small cell lung cancer and successfully met its primary endpoints of improving patient survival rates.
The company also went on to say that it will go on to seek approval in China. Tislelizumab has already been approved in the country for treatment-resistant Hodgkin lymphoma in patients that have already tried two previous cancer therapies.
Image source: Getty Images.
Source Fool.com